Welcome to the Working Group on New TB Drugs Blog
Posted in Front Lines of TB R&D, TB R&D Spotlight Interviews, Uncategorized, Video, Voices from the Fight to Stop Tuberculosis
Immunotherapeutic Vaccines, TB and China: Interview with Dr. Douglas Lowrie
This week we highlight an interview with Dr. Douglas Lowrie, a Senior Research Fellow at Fudan University’s Shanghai Public Health Clinical Center in China. He discusses the extent of the problem of TB in China and innovative research on enhancing TB treatment using immunotherapeutic vaccines.
TB R&D Weekly Update: Delamanid Shows Promise against Multidrug-Resistant TB
This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine. Delamanid (OPC-67683) is a new agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis. The abstract and overview of news coverage are presented, as well as, additional links to TB R&D news.
TB R&D Weekly Update: ICAAC and TB Drug Clinical Workshop
On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB drug development. Additional links to TB R&D are included.
Posted in Announcements, Early Drug Development, Front Lines of TB R&D, TB Drug Development, TB News, TB Treatment
First Chinese Product Development Partnership for TB, Malaria and HIV/AIDS Announced
Today on World TB Day, the International Scientific Exchange Foundation of China (ISEFC), announced the signing of a Memorandum of Understanding with the Global Alliance for TB Drug Development (TB Alliance) to establish the Global Health R&D Center of China (GHRC). This innovative center will focus on the development of treatments for the world’s leading infectious disease killers—tuberculosis, malaria, and HIV/AIDS.
-
Toppix TB News- TB, a neglected disease in Uganda 15 May 2013
- Dr. John: Medications, T.B, tinnitus 8 May 2013
- U.S. non-profit group to build tuberculosis center in Pyongyang 4 May 2013
- Predictors of tuberculosis (TB) and antiretroviral (ARV) medication... 26 Apr 2013
- Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr.... 26 Apr 2013
